| In Vitro |
PI3K/Akt/mTOR-IN-2 (compound 23) (0.5 - 100 μM; 72 hours) exhibits effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 is 2.29 μM[1]. PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1[1]. PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24, 48 and 72 hours) induces apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners[1]. PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 48 hours) increases the expression of Bax, and decreases the expression of Bcl-2 in MDA-MB-231 cells[1]. PI3K/Akt/mTOR-IN-2 (1 μM, 2 μM and 4 μM; 24 hours) induces mitochondria-dependent apoptosis in MDA-MB-231 cells through disruption of MMP, accumulation of ROS, depletion of GSH and elevation of intracellular Ca2+[1]. Cell Proliferation Assay Cell Line: PC3, BGC-823, A549, MCF-7, MDA-MB-231 cells and MCF-10A cells[1] Concentration: 0.5 - 100 μM Incubation Time: 72 hours Result: Exhibited effective anti-cancer activity with IC50s of 2.29 - 24.63 μM, of which, IC50 in MDA-MB-231 was 2.29 μM. Cell Cycle Analysis Cell Line: MDA-MB-231[1] Concentration: 1 μM, 2 μM and 4 μM Incubation Time: 24 hours Result: Induced growth inhibition of MDA-MB-231 cells by cell cycle arrest at G0/G1. Apoptosis Analysis Cell Line: MDA-MB-231[1] Concentration: 1 μM, 2 μM and 4 μM Incubation Time: 24, 48 and 72 hours Result: Induced apoptosis in MDA-MB-231 cells with both dose- and time-dependent manners. Western Blot Analysis Cell Line: MDA-MB-231[1] Concentration: 1 μM, 2 μM and 4 μM Incubation Time: 48 hours Result: Increased the expression of Bax, and decreased the expression of Bcl-2
|
